Cardinal Health lifts annual profit outlook on strength in specialty medicines unit
Nov 1 (Reuters) -Cardinal Health CAH.N raised its 2025 adjusted profit forecast on Friday as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit, sending the shares of the company up nearly 4% in premarket trading.
Drug distributors have been trying to diversify their operations and gain better footing in the specialty medicines market, focusing on treatments for complex conditions like rheumatoid arthritis and cancer, which have seen a growing demand in the United States.
The company struck a $1.12 billion deal in September to buy community cancer center operator Integrated Oncology Network to join its rivals McKesson MCK.N and Cencora COR.N in expanding into cancer care.
"The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year," CEO Jason Hollar said in a statement.
The company now expects 2025 adjusted earnings per share of $7.75 to $7.90, compared with its previous forecast of $7.55 to $7.70. Analysts were expecting an annual profit of $7.63 per share, according to data compiled by LSEG.
Cardinal Health expects 4% to 6% profit growth for the pharmaceutical and specialty solutions unit, compared with 1% to 3% growth forecast previously.
The company derives a substantial portion of its revenue from the unit, which brought in sales of $48 billion in the first quarter ended Sept. 30. The unit distributes branded and generic drugs, specialty medicines, and over-the-counter products.
"Cardinal Health started off fiscal year 2025 with a strong quarter, surpassing a fairly high bar heading into the print," Leerink Partners analyst Michael Cherny wrote in a note.
Total revenue in the quarter came in at $52.3 billion, beating analysts' average estimates of $50.9 billion.
On an adjusted basis, Cardinal Health reported a profit of $1.88 per share, beating expectations of $1.62 apiece.
Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
